Preparation method and application of exosome-like nano-vesicle-like sample derived from radix salviae miltiorrhizae

By preparing exosome-like nanovesicles derived from Danshen and co-culturing them with vascular endothelial cells, the problem of oxidative stress damage after endovascular interventional therapy was solved, and the protection and recovery of vascular endothelial cells were achieved.

CN119033842APending Publication Date: 2024-11-29TIANJIN CITY THIRD CENT HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411022224.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In existing technologies, procedures such as endovascular interventional therapy and vascular anastomosis can damage vascular endothelial cells and induce oxidative stress, leading to vascular injury.

Method used

Exosome-like nanovesicles derived from Salvia miltiorrhiza were prepared and purified by centrifugation and sucrose gradient centrifugation. The obtained nanovesicles were co-cultured with human aortic endothelial cells to inhibit oxidative stress damage.

Benefits of technology

It effectively inhibits the production of ROS after oxidative stress damage to vascular endothelial cells, protects vascular endothelial cells, reduces cell apoptosis and inflammation, and promotes vascular recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033842A_ABST
    Figure CN119033842A_ABST
Patent Text Reader

Abstract

The invention provides a preparation method and application of an exosome-like nano-vesicle sample derived from radix salviae miltiorrhizae, and relates to the technical field of exosome-like nano-vesicle biological preparations. The exosome-like nano-vesicle sample derived from radix salviae miltiorrhizae and human aortic endothelial cells are co-cultured; the compound can inhibit generation and apoptosis of ROS (reactive oxygen species) in cells after oxidative stress injury of vascular endothelial cells, and promote recovery of skeletal muscle after lower limb ischemia of mice. As a natural intercellular information carrier, the exosome-like nano-vesicles are relatively small in molecular structure and good in biocompatibility; compared with common drugs, the exosome-like nano-vesicles are high in bioavailability, contain multiple nucleic acid substances and have good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of exosome-like nanovesicle biological preparations, and specifically to a preparation method and application of exosome-like nanovesicles derived from Salvia miltiorrhiza. Background Art

[0002] Plant exosome-like nanovesicles (ELNs) are a type of membrane vesicles originating from eukaryotic plant cells. They have similar morphology, release mechanism and contents to extracellular vesicles from mammals. Since plants have a wide range of sources, plant-derived exosome-like nanovesicles have the potential for large-scale production. At the same time, ELNs extracted from medicinal plants are often rich in a variety of bioactive components, such as lipids, proteins, RNA and effective small molecules.

[0003] With the continuous development of science and technology, the extraction and separation technology of plant-derived exosome-like vesicles is being developed for plants with different sources and different extraction purposes. Since plant vesicles are natural nanoformulations, they have been shown to play an important role in the treatment of colitis, anti-tumor, antibacterial, liver disease, whitening and periodontitis, and have immunomodulatory properties. In addition, ELNs have good morphology and properties and can be used as low-toxic nanocarriers to achieve the delivery of exogenous drug molecules.

[0004] As a famous traditional medicinal plant, Salvia miltiorrhiza has a long history. According to research reports, it has multiple biological effects such as anti-inflammatory, antioxidant, cardioprotective, and neuroprotective. Intravascular interventional therapy, vascular anastomosis and other operations often damage vascular endothelial cells and induce oxidative stress in endothelial cells, further causing vascular damage. The application of Salvia miltiorrhiza-derived exosome-like nanovesicles to damaged vascular endothelial cells or to induce oxidative stress in endothelial cells has great application prospects. Summary of the invention

[0005] In view of this, the present application provides a method for preparing and applying exosome-like nanovesicles derived from Salvia miltiorrhiza, which solves the technical problem in the prior art of damaging vascular endothelial cells and inducing oxidative stress in vascular endothelial cells after operations such as intravascular interventional treatment and vascular anastomosis, thereby causing vascular damage.

[0006] According to the first aspect of the present application, the present application provides a use of exosome-like nanovesicles derived from Salvia miltiorrhiza in the preparation of a drug for alleviating oxidative stress damage to vascular endothelial cells.

[0007] In one embodiment, the exosome-like nanovesicles derived from Salvia miltiorrhiza are used in the preparation of a drug for alleviating oxidative stress damage to vascular endothelial cells.

[0008] In one embodiment, the exosome-like nanovesicles derived from Salvia miltiorrhiza inhibit ROS production in human aortic endothelial cells after oxidative stress injury of vascular endothelial cells.

[0009] According to the second aspect of the present application, the present application provides a method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza, and the preparation method comprises the following steps: preparing Salvia miltiorrhiza stock solution, squeezing Salvia miltiorrhiza juice and filtering to obtain Salvia miltiorrhiza stock solution; preparing exosome-like nanovesicles, centrifuging the filtered Salvia miltiorrhiza stock solution to obtain exosome-like nanovesicles; purifying exosome-like nanovesicles, purifying the extracted exosome-like nanovesicles using sucrose density gradient centrifugation.

[0010] In one embodiment, the preparation process of the salvia miltiorrhiza stock solution is as follows: wash and peel the salvia miltiorrhiza and then sterilize it together with the instrument with alcohol; cut the sterilized salvia miltiorrhiza into small pieces with the sterilized instrument; add a certain amount of PBS to the salvia miltiorrhiza cut into small pieces and squeeze the juice to obtain the squeezed juice; filter the squeezed juice with sterile gauze to obtain the salvia miltiorrhiza stock solution.

[0011] In one embodiment, the preparation process of the exosome-like nanovesicles is as follows: the Danshen stock solution is taken out and moved to a first centrifuge tube, and centrifuged at 800-1200×g for 10-15 minutes at 4°C to obtain a first centrifuge liquid; the supernatant of the first centrifuge liquid is moved to a second centrifuge tube, and centrifuged again at 2500-3500×g for 20-40 minutes at 4°C to obtain a second centrifuge liquid; the supernatant of the second centrifuge liquid is moved to a third centrifuge tube, and centrifuged again at 10,000×g at 4°C. 20-40min to obtain a third centrifuge; the supernatant of the third centrifuge is taken out and filtered to obtain a filtrate; the filtrate is transferred to a fourth centrifuge tube, and ultracentrifuged at 100,000×g for 70-90min at 4°C to obtain a fourth centrifuge; the supernatant of the fourth centrifuge is removed and resuspended, and ultracentrifuged again at 100,000×g for 70-90min at 4°C to obtain a fifth centrifuge; the supernatant of the fifth centrifuge is removed and resuspended again to obtain exosome-like nanovesicles.

[0012] In one embodiment, the preparation process of the exosome-like nanovesicles is as follows: the Danshen stock solution is taken out and moved to a first centrifuge tube, centrifuged at 800×g for 10 minutes to obtain a first centrifuge; the supernatant of the first centrifuge is moved to a second centrifuge tube, centrifuged at 2500×g for 30 minutes to obtain a second centrifuge; the supernatant of the second centrifuge is moved to a third centrifuge tube, centrifuged at 10000×g for 30 minutes to obtain a third centrifuge; the supernatant of the third centrifuge is taken out and filtered through a 0.22um filter membrane to obtain a filtrate; the filtrate is moved to a fourth centrifuge tube, ultracentrifuged at 100,000×g for 80 minutes to obtain a fourth centrifuge; after removing the supernatant of the fourth centrifuge and resuspending, ultracentrifuging again at 100,000×g for 80 minutes to obtain a fifth centrifuge; the supernatant of the fifth centrifuge is removed and resuspended again to obtain an exosome-like nanovesicle solution.

[0013] In one embodiment, the purification process of exosome-like nanovesicles includes: filling the volume of the exosome-like nanovesicle solution to 500 μL with pre-cooled 1×PBS to obtain a mixed solution; adding the mixed solution to a gradient sucrose solution and centrifuging for 80 minutes; taking out 300 μL of the solution at the junction of the sucrose gradient, centrifuging again for 80 minutes, removing the supernatant precipitate and resuspending.

[0014] The present application provides a preparation method and application of exosome-like nanovesicles derived from Salvia miltiorrhiza, and relates to the technical field of exosome-like nanovesicle biological preparations. After the exosome-like nanovesicles derived from Salvia miltiorrhiza are co-cultured with human aortic endothelial cells, the production of intracellular ROS after oxidative stress damage of vascular endothelial cells can be inhibited. Exosome-like nanovesicles serve as natural intercellular information carriers, have a small molecular structure and good biocompatibility. Compared with ordinary drugs, exosome-like nanovesicles have high bioavailability and contain a variety of nucleic acid substances, and have good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The figure shows a flow chart for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza provided in one embodiment of the present application;

[0016] Figure 2 Shown is a transmission electron microscopy image of exosome-like nanovesicles derived from Salvia miltiorrhiza provided in Experimental Example 1 of the present application;

[0017] Figure 3 Shown is the particle size distribution diagram of the exosome-like nanovesicles derived from Salvia miltiorrhiza provided in Experimental Example 1 of the present application.

[0018] Figure 4 The above is a ROS fluorescence image after vascular endothelial cell injury modeling and intervention with exosome-like nanovesicles provided in Experimental Example 2;

[0019] Figure 5 The fluorescence images of cell apoptosis after endothelial cell injury modeling and hydrogen peroxide intervention using exosome-like nanovesicles provided in Experimental Example 3 are shown;

[0020] Figure 6 The figure shows the hematoxylin-eosin staining of the gastrocnemius muscle section of the mouse lower limb ischemia model provided in Experimental Example 4;

[0021] Figure 7 Shown is a Masson staining image of the gastrocnemius muscle section of the mouse hind limb ischemia model provided in Experimental Example 5. DETAILED DESCRIPTION

[0022] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0023] Example 1

[0024] Step 100: Wash and peel 500 g of Salvia miltiorrhiza and sterilize it with alcohol together with a slicing instrument; cut the sterilized Salvia miltiorrhiza into small pieces with a sterilized slicing instrument in a clean bench, add 600 ml of phosphate buffered saline (PBS) to the small pieces of Salvia miltiorrhiza. ) The juice was then squeezed to obtain 300 mL of squeezed juice, which was filtered using sterile gauze to obtain Danshen stock solution.

[0025] Step 200, remove the Danshen stock solution and move it to a first centrifuge tube, centrifuge it at 800×g for 10 min at 4°C to obtain a first centrifuge; remove the supernatant of the first centrifuge to a second centrifuge tube, centrifuge it at 2500×g for 30 min at 4°C to obtain a second centrifuge; remove the supernatant of the second centrifuge to a third centrifuge tube, centrifuge it at 10000×g for 20-40 min at 4°C to obtain a third centrifuge; remove the supernatant of the third centrifuge and centrifuge it at 0 .22um filter membrane to obtain a filtrate; the filtrate is transferred to a fourth centrifuge tube, and ultracentrifuged at 100,000×g for 80 min at 4°C to obtain a fourth centrifuge; the supernatant of the fourth centrifuge is removed, and the mixture is resuspended with 30 mL of pre-cooled 1×PBS, and an ultraspeed rotor is selected, and ultracentrifuged again at 100,000×g for 80 min at 4°C to obtain the fifth centrifuge; the supernatant of the fifth centrifuge is removed and resuspended again to obtain an exosome-like nanovesicle solution;

[0026] Step 300, use pre-cooled 1×PBS to make up the volume of the exosome-like nanovesicle solution to 500 μL to obtain a mixed solution; add the mixed solution to the gradient sucrose solution and centrifuge for 80 minutes; take out 300 μL of the solution at the junction of the sucrose gradient, centrifuge again for 80 minutes, remove the supernatant precipitate and resuspend it, that is, exosome-like nanovesicles.

[0027] Experimental Example 1

[0028] The prepared exosome-like nanovesicles derived from Danshen were placed under a transmission electron microscope (TEM) for observation. Figure 2 The figure shows a transmission electron micrograph of exosome-like nanovesicles derived from Danshen provided in Experimental Example 1 of the present application. Figure 3 The particle size distribution diagram of the exosome-like nanovesicles derived from Danshen provided in Experimental Example 1 of this application is shown as follows Figure 2 as well as Figure 3 As shown, the particle size of the exosome-like nanovesicles derived from Salvia miltiorrhiza is mainly distributed between 30-200 nm, which is consistent with the standard size of exosomes, indicating that the exosome-like nanovesicles prepared according to the method of Example 1 are exosome-like nanovesicles derived from Salvia miltiorrhiza.

[0029] Experimental Example 2

[0030] Human aortic endothelial cell line was provided by the Institute of Biomedical Engineering, Peking Union Medical College. Hydrogen peroxide (H2O2) solution was used to intervene in the adherent human aortic endothelial cell line to simulate cellular ROS (reactive oxygen species) damage. Exosome-like nanovesicles derived from Salvia miltiorrhiza were added and co-cultured with human aortic endothelial cells for 24 hours. Then, the ROS level of human aortic endothelial cells was tested using a ROS detection kit (Biyuntian, S0033). The green fluorescence intensity represents the ROS level in the cells. It can be seen that the exosome-like nanovesicles derived from Salvia miltiorrhiza can help inhibit the production of intracellular ROS after oxidative stress injury of vascular endothelial cells, thereby protecting vascular endothelial cells from damage. Figure 4 The above is a ROS fluorescence image after endothelial cell injury modeling and intervention with exosome-like nanovesicles; Figure 4 As shown in the figure, compared with the control group, the green fluorescence of the cells was significantly enhanced after intervention with hydrogen peroxide solution, indicating that the ROS content of the cells increased. After co-culture with exosome-like nanovesicles derived from Salvia miltiorrhiza, the green fluorescence of the cells decreased significantly, indicating that the exosome-like nanovesicles derived from Salvia miltiorrhiza have good ROS scavenging ability, thereby protecting vascular endothelial cells from ROS damage.

[0031] After intravascular interventional treatment, vascular anastomosis and other operations, the use of exosome-like nanovesicles derived from Salvia miltiorrhiza or drugs containing exosome-like nanovesicles derived from Salvia miltiorrhiza can inhibit the production of ROS in human aortic endothelial cells after oxidative stress injury of vascular endothelial cells, thereby not damaging the vascular endothelial cells or inducing oxidative stress in the vascular endothelial cells, thereby avoiding vascular damage.

[0032] Experimental Example 3

[0033] The adherent human aortic endothelial cell line was intervened with hydrogen peroxide solution to create a cell oxidative stress injury model. The exosome-like nanovesicles derived from Salvia miltiorrhiza were added and co-cultured with human aortic endothelial cells for 24 hours. Then, the Tunel kit (Biyuntian, C1088) was used to test the apoptosis level of human aortic endothelial cells after hydrogen peroxide intervention, that is, to detect the breakage of nuclear DNA in tissues and cells during the late stage of apoptosis. Figure 5 The fluorescence images of cell apoptosis after endothelial cell injury modeling and after hydrogen peroxide intervention using exosome-like nanovesicles are shown in Figure 2. Figure 5 As shown, the green fluorescence intensity represents the level of cell apoptosis. Human aortic endothelial cells intervened with hydrogen peroxide showed green fluorescence. The green fluorescence expression of human aortic endothelial cells decreased significantly after intervention with exosome-like nanovesicles derived from Salvia miltiorrhiza. This shows that exosome-like nanovesicles derived from Salvia miltiorrhiza can help inhibit cell apoptosis after oxidative stress injury of vascular endothelial cells.

[0034] Experimental Example 4

[0035] The mouse lower limb ischemia model was used to test the repair effect of Danshen-derived exosome-like nanovesicles on skeletal muscle after ischemia. The modeling method is as follows: first, the mouse is anesthetized, the skin is depilated, and disinfected. The mouse skin is incised with a scalpel, and the upper and lower ends of the mouse femoral artery are ligated with surgical sutures, and the femoral artery is cut and the skin is sutured. Danshen-derived exosome-like nanovesicles are injected into the skeletal muscle of the mouse leg once every two days. After 14 days, the gastrocnemius muscle of the mouse is sampled. After the mouse gastrocnemius muscle is sampled, it is prepared into paraffin sections and stained using a hematoxylin-eosin (HE) staining kit (Solebo G1120). Figure 6 The figure shows the hematoxylin-eosin staining of the gastrocnemius muscle section of the mouse hind limb ischemia model. Figure 6 As shown, Figure 6 The blue colored cells are inflammatory cells. Compared with the injury group, the number of inflammatory cells in the gastrocnemius muscle sections of the ELNs group was significantly decreased, indicating that the exosome-like nanovesicles derived from Salvia miltiorrhiza can effectively promote skeletal muscle recovery after lower limb ischemia in mice.

[0036] Experimental Example 5

[0037] The gastrocnemius muscles of mice were collected and prepared into paraffin sections and stained using the Masson staining kit (Solebol G1340). Figure 7 The following is a Masson staining image of the gastrocnemius muscle section in the mouse hind limb ischemia model. Figure 7 As shown, Figure 7 The blue part is the fibrotic part. Compared with the injury group, the degree of gastrocnemius fibrosis in the ELNs group was significantly decreased, indicating that the exosome-like nanovesicles derived from Salvia miltiorrhiza can effectively protect the skeletal muscle fibrosis after lower limb ischemia in mice.

[0038] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, etc. made within the spirit and principles of the present application shall be included in the protection scope of the present application.

Claims

1. Application of exosome-like nanovesicles derived from Salvia miltiorrhiza in the preparation of drugs for alleviating oxidative stress damage of vascular endothelial cells.

2. Use of the exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 1 in the preparation of a drug for alleviating oxidative stress damage of vascular endothelial cells, It is characterized in that The use of the exosome-like nanovesicles derived from salvia miltiorrhiza in the preparation of a drug for alleviating oxidative stress damage to vascular endothelial cells.

3. Use of the exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 2 in the preparation of a drug for alleviating oxidative stress damage of vascular endothelial cells, It is characterized in that The exosome-like nanovesicles derived from Danshen inhibit the production of ROS in human aortic endothelial cells after oxidative stress injury of vascular endothelial cells.

4. A method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza, It is characterized in that The method for preparing the exosome-like nanovesicles derived from Danshen comprises the following steps: Preparation of Danshen stock solution: squeeze the Danshen juice and filter it to obtain Danshen stock solution; Preparation of exosome-like nanovesicles: centrifugation is performed on the filtered Danshen stock solution to obtain exosome-like nanovesicles; Purification of exosome-like nanovesicles: Sucrose density gradient centrifugation was used to purify the extracted exosome-like nanovesicles.

5. The method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 4, It is characterized in that, The preparation process of the salvia miltiorrhiza stock solution is as follows: wash and peel the salvia miltiorrhiza and then sterilize it together with the instrument with alcohol; cut the sterilized salvia miltiorrhiza into small pieces with the sterilized instrument; add a certain amount of PBS to the salvia miltiorrhiza cut into small pieces and squeeze the juice to obtain the squeezed juice; filter the squeezed juice with sterile gauze to obtain the salvia miltiorrhiza stock solution.

6. The method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 4, It is characterized in that The preparation process of the exosome-like nanovesicles is as follows: The Danshen stock solution was taken out and moved into a first centrifuge tube, and centrifuged at 800-1200×g for 10-15 min at 4°C to obtain a first centrifuge solution; The supernatant of the first centrifuge liquid was transferred to a second centrifuge tube, and centrifuged again at 2500-3500×g for 20-40 min at 4°C to obtain a second centrifuge liquid; The supernatant of the second centrifuge liquid was transferred to a third centrifuge tube, and centrifuged again at 10,000×g for 20-40 min at 4°C to obtain a third centrifuge liquid; The supernatant of the third centrifuge is taken out and filtered to obtain a filtrate; The filtrate was transferred to a fourth centrifuge tube, and ultracentrifuged at 100,000×g for 70-90 min at 4°C to obtain a fourth centrifuge liquid; After removing the supernatant of the fourth centrifugation liquid and resuspending, ultracentrifuging again at 100,000×g for 70-90 min at 4° C. to obtain the fifth centrifugation liquid; The supernatant of the fifth centrifugation solution was removed and the mixture was resuspended again to obtain exosome-like nanovesicles.

7. The method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 6, It is characterized in that The preparation process of the exosome-like nanovesicles is as follows: The Danshen stock solution was taken out and moved to the first centrifuge tube, and centrifuged at 800×g for 10 min to obtain the first centrifuge solution; The supernatant of the first centrifuge liquid was transferred to a second centrifuge tube and centrifuged at 2500×g for 30 min to obtain a second centrifuge liquid; The supernatant of the second centrifuge liquid was transferred to a third centrifuge tube, and centrifuged at 10,000 × g for 30 min to obtain a third centrifuge liquid; The supernatant of the third centrifuge is taken out and filtered through a 0.22 um filter membrane to obtain a filtrate; The filtrate was transferred to a fourth centrifuge tube and ultracentrifuged at 100,000×g for 80 min to obtain a fourth centrifuge liquid; After removing the supernatant of the fourth centrifugation liquid and resuspending, ultracentrifugation was performed again at 100,000×g for 80 min to obtain the fifth centrifugation liquid; The supernatant of the fifth centrifugation solution was removed and resuspended again to obtain an exosome-like nanovesicle solution.

8. The method for preparing exosome-like nanovesicles derived from Salvia miltiorrhiza according to claim 4, It is characterized in that The purification process of exosome-like nanovesicles includes: using pre-cooled 1×PBS to make up the volume of the exosome-like nanovesicle solution to 500 μL to obtain a mixed solution; adding the mixed solution to a gradient sucrose solution and centrifuging for 80 minutes; taking out 300 μL of the solution at the junction of the sucrose gradient, centrifuging again for 80 minutes, removing the supernatant precipitate and resuspending.

Citation Information

Patent Citations

  • Application of tanshinol derivatives in preparation of drug for preventing cardiovascular-related diseases

    CN103284989A

  • Application of miltirone to prepare medicine protecting vascular endothelial cells

    CN104095836A

  • Application of salvia miltiorrhiza-derived exosome-like nanovesicles in preparation of anti-GC myopathy drugs

    CN117982555A